HUMAN RECOMBINANT AMY2 RECEPTOR
MULTISCREEN™ STABLE CELL LINES
1 vial (2 x 106) frozen cells
Cell Banker 2 (Amsbio 11891)
Full-length Human CALCR cDNA (GenBank Accession Number NM_001742) with FLAG-tag sequence at the N-terminus and Full-length Human receptor activity modifying protein 2 (RAMP2) cDNA (GenBank Accession Number NM_005854.2) with myc-tag at the C-terminus
Liquid nitrogen upon receiving
Propagation Medium: DME/F12, 10% FBS, 10 µg/mL puromycin, 250µg/mL hygromycin
Background: Amylin receptors are multimeric complexes and have been closely associated with Calcitonin receptor (CT). CT, in the presence of the receptor activity modifying proteins (RAMP1, RAMP2 and RAMP3), forms pharmacologically distinct Amylin subtypes (AMY1, AMY2 and AMY3) which acts as a high affinity receptor for amylin, a hormone secrete by B cell of pancreas that has a major role in glucose regulation.
Application: Functional assays
Figure 1. Dose-dependent increase of intracellular cAMP level upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01). Figure 2. Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Morfis et al. (2008) Receptor Activity-Modifying Proteins Differentially Modulate the G Protein-coupling Efficiency of Amylin Receptors. Endocrinology: 149(11):5423–5431.
Hay et al. (2005) Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes. Mol Pharmacol 67:1655–1665.
Gorn et al. (1992) Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 90:1726-1735.
RJ Bailey et al.(2011). Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. BJP 166:151–167